Table 3.

Change from baseline in signs of atrophogenicity by visit (safety population)

Treatment	Baseline atrophy score	Change from baseline in signs of atrophogenicity by visit: Atrophy score
		Visit 3 (day 7), n (%)			Visit 4 (day 14), n (%)			Visit 5 (day 21), n (%)
		0	1	2	0	1	2	0	1	2
Clobetasol propionate 0.025% formulation 5	0 (n = 26)	25 (96.2)	0	0	20 (76.9)	1 (3.8)	0	17 (65.4)	2 (7.7)	0
	1 (n = 3)	0	3 (100)	0	0	3 (100.0)	0	1 (33.3)	2 (66.7)	0
Clobetasol propionate 0.025% formulation 13	0 (n = 23)	22 (95.7)	0	0	15 (65.2)	2 (8.7)	0	12 (52.2)	3 (13.0)	0
	1 (n = 5)	1 (20.0)	4 (80.0)	0	4 (80.0)	1 (20.0)	0	4 (80.0)	1 (20.0)	0
	2 (n = 1)	0	0	1 (100)	1 (100)	0	0	1 (100)	0	0
Clobetasol propionate 0.05% cream	0 (n = 26)	22 (84.6)	0	0	16 (61.5)	1 (3.8)	0	11 (42.3)	2 (7.7)	1 (3.8)
	1 (n = 4)	1 (25.0)	3 (75.0)	0	2 (50)	2 (50.0)	0	4 (100)	0	0

Treatment	Baseline telangiectasia score	Change from baseline in signs of atrophogenicity by visit: Telangiectasia score
		Visit 3 (day 7), n (%)			Visit 4 (day 14), n (%)			Visit 5 (day 21), n (%)
		0	1	2	0	1	2	0	1	2
Clobetasol propionate 0.025% formulation 5	0 (n = 29)	28 (96.6)	0	0	24 (82.8)	0	0	20 (69.0)	2 (6.9)	0
Clobetasol propionate 0.025% formulation 13	0 (n = 28)	27 (96.4)	0	0	21 (75.0)	1 (3.6)	0	17 (60.7)	3 (10.7)	0
	2 (n = 1)	0	0	1 (100)	1 (100)	0	0	1 (100)	0	0
TMV cream	0 (n = 30)	26 (86.7)	0	0	21 (70.0)	0	0	16 (53.3)	2 (6.7)	0

0, none; 1, slight; 2, moderate; 3, pronounced; 4, very pronounced.